Emergent BioSolutions | EBS - Interest Expense On Debt


Emergent BioSolutions reported $17.9M in Interest Expense on Debt for its fiscal quarter ending in March of 2023.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Akebia Therapeutics 362.52M 357.69M Mar/2026
ALKERMES USD 25.92M 5.03M Jun/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Amarin USD 3K 5K Dec/2024
ANI Pharmaceuticals USD 4.41M 316K Dec/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Exelixis USD 23.4M 3.9M Sep/2023
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
Heron Therapeutics USD 600K 100K Dec/2024
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
Lonza CHF 84M 14M Jun/2025
Merck USD 525M 46M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Myriad Genetics USD 4.4M 600K Dec/2025
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pacira USD 3.62M 77K Jun/2026
Pfizer USD 667M 4M Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Sanofi EUR 287M 109M Jun/2026
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
United Therapeutics USD 3.1M 100K Dec/2025
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025